Stroke After Carotid Stenting and Endarterectomy in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)  by Hill, M.D. et al.
JOURNAL OF VASCULAR SURGERY
894 Abstracts March 2013Conclusion: The mitogen-activated protein kinase MAPK/extra
cellular signal-related kinase (ERK) pathway is an important modulator of
metalloproteinases (MMPs) during abdominal aortic aneurysm (AAA)
formation.
Summary: The mechanism of AAA formation is clearly multifactorial.
However, matrix-degrading metalloproteinases (MMPs), especially
MMP2 and MMP9, appear to be important players in AAA formation.
The MAPK signaling pathway regulates MMPs. There are four basic
MAPK signaling pathways (Murphy LO, et al, Trends Bicochem Sci
2006;31:268-75). Some MAPK signaling pathways have been better
studied than others. For instance, it appears phospho-c-Jun N-terminal
kinase (JNK) is important for activation of MMP9 and therefore potentially
important in AAA formation (Yoshimura K et al, Nat Med 2005;
11:1330-8). ERK modulates MMPs and recruits neutrophils, with resulting
release of cytokines at sites of inﬂammation. Such inﬂammation has been has
been associated with AAA formation. The authors hypothesized phosphor-
ylation of ERK may be an important event in MMP activation and, there-
fore, in AAA formation. The authors used a mouse model of AAA.
C57BL/6 male mice underwent elastase or heat-inactivated elastase aortic
perfusion (n ¼ 9 per group). Smooth muscle cells from the mice were trans-
fected with ERK-1 and 2 siRNA, with and without elastase treatment.
Mouse and human aortic tissue were analyzed by Western blots, zymo-
grams, and immunohistochemistry. Statistical analysis was done with Graph-
Pad and Image J software. Western blot and immunohistochemistry
documented increased phosphomitogen activated protean kinase kinase-
1/2 (pERK-12; 153%; P ¼ .270 by Western blot) and pERK (171%; P ¼
.004 by Western blot) in elastase-perfused aortas. Male ERK-1/ mice
underwent elastase perfusion, and aortic diameter was determined at day
14. ERK-1/ mice failed to develop AAA. Histologic analysis depicted
intact collagen and elastin ﬁbers in the aortas of these mice. Zymography
of aortas of elastase-treated ERK-1/ mice showed lower levels of pro-
MMP2 (P < .005) and active MMP2 (P < .0001), as well as pro-MMP9
(P ¼ .037) compared with c57BL/6 mice. Transfection of ERK-1 and
ERK-2 by short interfering RNA transfection reduced formation of pro-
MMP2 and active MMP2 (P < .01) in both aortic smooth muscle cells
treated with elastase in vitro (P < .01). Human AAA tissue had elevated
levels of pMEK-1/2 (150%; P ¼ .014) and pERK (159%; P ¼ .013)
compared with controlled tissues.
Comment: Targeting the underline biochemical mechanisms of AAA
formation is receiving increasing attention. There are extensive data on the
role of MMPs and AAA formation but little actual data on potential regu-
lators of MMPs. The data here suggest that targeting ERK pathways insuch a way as to inhibit expression or phosphorylation of ERK isoforms is
another potential method to possibly prevent AAA formation in at-risk
patients.Stroke After Carotid Stenting and Endarterectomy in the Carotid
Revascularization Endarterectomy Versus Stenting Trial (CREST)
Hill MD, Brooks W, Mackey A, and the CREST Investigators. Circulation
2012;126:3054-3061.
Conclusion: After carotid intervention in the CREST study, stroke,
particularly severe stroke, was uncommon but was associated with signiﬁ-
cant morbidity and independently associated with a nearly threefold increase
in future death.
Summary: Multiple studies now document stroke is a more frequent
complication of carotid stenting than carotid endarterectomy. In the CREST
trial, strokes were more common after stenting than after endarterectomy,
but myocardial infarctions were more common after endarterectomy. Stroke
had a greater impact than myocardial infarction on quality of life, based on
assessment of the Short Form-36 physical and mental subscales. In this
report, the authors document details regarding strokes occurring in the
CREST trial with respect to stroke type, severity, and other characteristics.
In the CREST trial, stroke was adjudicated by a panel of board-certiﬁed
vascular neurologists, with a secondary central review of brain imaging
studies. Stroke type, laterality, timing, and outcome were reported. Peripro-
cedural stroke occurred among 81 of the 2502 patients randomized in
CREST and among 69 of the 2272 in the present analysis. Of these strokes,
56 (81%,) were minor, 62 (90%) were ischemic, and 65 (94%) were in the
anterior circulation and 51 (88%) were ipsilateral to the treated artery. Seven
hemorrhages occurred at 3 to 21 days after the procedure, and ﬁve were
fatal. Major stroke occurred in 13 of 2272 patients (0.6%). The 4-year
mortality after stoke was 21.1% compared with 11.6% for those without
stroke. Adjusted risk of death at 4 years was higher after periprocedural
stroke (hazard ratio, 2.78; 95% conﬁdence interval, 1.63-4.76).
Comment: The authors previously reported that myocardial infarc-
tion, including biomarker-only myocardial infarction, was associated with
an increased risk of long-term death in the CREST patients. Now, they
also report that strokes, even though most are minor, are also associated
with an increased risk of long-term death in the CREST patients. It is still
unknown whether these periprocedural events in themselves increase the
risk of long-term mortality or are merely markers of more advanced or
aggressive generalized atherosclerotic disease.
